Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients Under Three Versus Six Months of Adjuvant Treatment

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jul 24

PMID 34298766

Citations 5

Authors

Asimina Koulouridi

Ippokratis Messaritakis

Emmanouil Theodorakis

Maria Chondrozoumaki

Maria Sfakianaki

Nikolaos Gouvas

John Tsiaoussis

Dimitrios Mavroudis

Maria Tzardi

John Souglakos

Affiliations

Soon will be listed here.

Abstract

Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiority of three over six months treatment with FOLFOX or CAPOX, in stage III CRC patients. Peripheral blood samples from 121 patients were collected, at three time points during treatment and evaluated for circulating tumor cells (CTCs) and microbial DNA detection (16S rRNA, , , ). Of all patients, 41.3% and 58.7% were treated with FOLFOX and CAPOX, respectively. CTCs were significantly decreased and increased after three and six months of treatment, respectively. CAPOX tends to reduce the CTCs after 3 months, whereas there is a statistically significant increase of CTCs in patients under FOLFOX after 6 months. A significant correlation was demonstrated between microbial DNA detection and both CTCs detection at baseline and CTCs increase between baseline and three months of treatment. To conclude, the current study provides additional evidence of non-inferiority of three over 6 months of treatment, mainly in patients under CAPOX.

Citing Articles

Circulating Bacterial DNA in Colorectal Cancer Patients: The Potential Role of .

Koliarakis I, Lagkouvardos I, Vogiatzoglou K, Tsamandouras I, Intze E, Messaritakis I Int J Mol Sci. 2024; 25(16).

PMID: 39201711 PMC: 11354820. DOI: 10.3390/ijms25169025.

Exploring Gut Microbiome Composition and Circulating Microbial DNA Fragments in Patients with Stage II/III Colorectal Cancer: A Comprehensive Analysis.

Messaritakis I, Koulouris A, Boukla E, Vogiatzoglou K, Lagkouvardos I, Intze E Cancers (Basel). 2024; 16(10).

PMID: 38792001 PMC: 11119035. DOI: 10.3390/cancers16101923.

Circulating Bacterial DNA as Plasma Biomarkers for Lung Cancer Early Detection.

Zhou H, Liao J, Leng Q, Chinthalapally M, Dhilipkannah P, Jiang F Microorganisms. 2023; 11(3).

PMID: 36985157 PMC: 10058358. DOI: 10.3390/microorganisms11030582.

Investigation of Microbial Translocation, and Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients.

Messaritakis I, Koulouridi A, Boukla E, Sfakianaki M, Vogiatzoglou K, Karagianni M Cancers (Basel). 2022; 14(18).

PMID: 36139567 PMC: 9496848. DOI: 10.3390/cancers14184407.

Circulating Bacterial DNA: A New Paradigm for Cancer Diagnostics.

Glyn T, Purcell R Front Med (Lausanne). 2022; 9:831096.

PMID: 35445046 PMC: 9013860. DOI: 10.3389/fmed.2022.831096.

References

Papadaki M, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos P, Mavroudis D . Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer. 2014; 14:651. PMC: 4161777. DOI: 10.1186/1471-2407-14-651. View

Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F . Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2018; 82(5):767-775. DOI: 10.1007/s00280-018-3666-9. View

Grothey A . Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003; 30(4 Suppl 15):5-13. DOI: 10.1016/s0093-7754(03)00399-3. View

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

Ding Y, Li W, Wang K, Xu C, Hao M, Ding L . Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. Biomed Res Int. 2020; 2020:6843180. PMC: 7085834. DOI: 10.1155/2020/6843180. View

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J . The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Ann Oncol. 2018; 29(5):1099-1107. PMC: 6864492. DOI: 10.1093/annonc/mdy064. View

Haller D, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29(11):1465-71. DOI: 10.1200/JCO.2010.33.6297. View

Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

10.

Baek D, Kim G, Song G, Han I, Park E, Kim H . Clinical Potential of Circulating Tumor Cells in Colorectal Cancer: A Prospective Study. Clin Transl Gastroenterol. 2019; 10(7):e00055. PMC: 6708664. DOI: 10.14309/ctg.0000000000000055. View

11.

Bleday R, Song J, Walker E, Salcedo B, Thomas P, Wilson R . Characterization of a new monoclonal antibody to a cell surface antigen on colorectal cancer and fetal gut tissues. Cancer. 1986; 57(3):433-40. DOI: 10.1002/1097-0142(19860201)57:3<433::aid-cncr2820570305>3.0.co;2-q. View

12.

Bruns T, Reuken P, Stengel S, Gerber L, Appenrodt B, Schade J . The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int. 2016; 36(8):1133-42. DOI: 10.1111/liv.13095. View

13.

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga J . Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017; 22(3):421-430. DOI: 10.1007/s10147-017-1105-2. View

14.

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

15.

Dizdar L, Fluegen G, van Dalum G, Honisch E, Neves R, Niederacher D . Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single-center study. Mol Oncol. 2019; 13(7):1548-1558. PMC: 6599844. DOI: 10.1002/1878-0261.12507. View

16.

Massague J, Obenauf A . Metastatic colonization by circulating tumour cells. Nature. 2016; 529(7586):298-306. PMC: 5029466. DOI: 10.1038/nature17038. View

17.

Sobrero A, Douillard J . Reply to the letter to the editor: 'The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?' By P. Trendsz et al. Ann Oncol. 2018; 29(8):1883-1884. DOI: 10.1093/annonc/mdy213. View

18.

Nanduri L, Hissa B, Weitz J, Scholch S, Bork U . The prognostic role of circulating tumor cells in colorectal cancer. Expert Rev Anticancer Ther. 2019; 19(12):1077-1088. DOI: 10.1080/14737140.2019.1699065. View

19.

Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A . Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015; 33(35):4176-87. DOI: 10.1200/JCO.2015.63.4238. View

20.

Jia S, Zhang R, Li Z, Li J . Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget. 2017; 8(33):55632-55645. PMC: 5589689. DOI: 10.18632/oncotarget.17184. View